Acne Vulgaris is a common skin disorder characterized by the formation of pimples, blackheads, cysts, and nodules. Although it predominantly affects adolescents, it can occur at any age. The condition arises due to excessive sebum production and blocked hair follicles, which result in inflammation. While acne itself is typically not life-threatening, it can significantly affect an individual’s quality of life by causing psychological distress, scarring, and social stigma. Treatment mainly aims to reduce inflammation, bacterial load, and sebum secretion.

Explore key stats, market drivers, and emerging drugs—all in one visual!: Click Here

Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the 7MM from 2020 to 2034 includes:

• Total prevalent cases of Acne Vulgaris
  
• Total diagnosed prevalent cases of Acne Vulgaris
  
• Gender-specific diagnosed prevalent cases of Acne Vulgaris
  
• Severity-specific diagnosed prevalent cases of Acne Vulgaris
  
• Treatable cases of Acne Vulgaris
  

Acne Vulgaris Epidemiology
In 2023, roughly 140.2 million cases of Acne Vulgaris were reported across the 7MM, with the US accounting for approximately 69.5 million cases. These figures are projected to increase over the forecast period.

In the 7MM, diagnosed cases of Acne Vulgaris were more common in females, who made up 63% of total cases.

The severity distribution of Acne Vulgaris in the 7MM was as follows:

• Moderate cases represented the largest share, accounting for 45% of diagnosed cases.
  
• Severe cases were the least common, comprising only 10% of total cases.

One graphic, all the essentials—click to explore!: Click Here

Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was around USD 4.26 billion in 2023.

Acne Vulgaris Market Drivers
The emergence of novel therapies, including SB204, DMT310, and BTX 1503, is anticipated to improve treatment options by providing more targeted, effective, and safer solutions for Acne Vulgaris.

Increasing awareness about the condition, especially its psychological effects, along with enhanced diagnostic techniques, is expected to propel growth in the Acne Vulgaris treatment market.

Acne Vulgaris Market Barriers
The varied clinical presentations of Acne Vulgaris and inconsistent responses to treatment, particularly in moderate and severe cases, complicate the development and regulatory approval of therapies, resulting in uncertain treatment outcomes.

High costs associated with newer and advanced therapies, combined with limited access to care in some regions, may restrict market expansion.

Acne Vulgaris Emerging Therapies

• SB204
  
• DMT310
  
• BTX 1503
  
• B244
  
• BPX-01
  
• And others
  

Acne Vulgaris Key Players

• Pelthos Therapeutics
  
• Dermata Therapeutics
  
• Botanix Pharmaceuticals
  
• AOBiome LLC
  
• BioPharmX
  
• Timber Pharmaceuticals
  
• And others
  

Grab your free copy of the infographic—essential for any analyst!: Click Here